CoChat
Sign Up
Cited by 310Alzheimer's disease research and treatmentsPluripotent Stem Cells ResearchDown syndrome and intellectual disability research

A Human Stem Cell Model of Early Alzheimer’s Disease Pathology in Down Syndrome

Open access
Shi, Yichen, Kirwan, Peter, Smith, James, MacLean, Glenn, Orkin, Stuart H., Livesey, Frederick J.·2012·Science Translational Medicine
DOI 10.1126/scitranslmed.3003771PMC PMC4129935
Open this paper in CoChat — free account

Abstract

Cultured cerebral cortex neurons generated from human Down syndrome induced pluripotent stem cells rapidly develop Alzheimer’s disease pathologies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3003771

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Results from induced pluripotent stem cell studies of neurogenesis are discordant: the generation of neurons from induced pluripotent stem cells has been reported in some studies to be impaired and in others not to be impaired, which may be explained by technical differences in the cell lines and protocols used.

    “However, results from these studies are discordant: the generation of neurons from iPSCs has been reported in some studies to be impaired74,77–79 and in others not to be impaired75,80,81, which may be explained by technical differences in the cell lines and protocols used (see Box 1).”

    From Consequences of trisomy 21 for brain development in Down syndrome (2024) · cites this paper as [80]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 40 · Cited by 310

Research works printed but not linked: 29

  1. [1]Selkoe DJ Alzheimer’s disease Cold Spring Harb Perspect Biol 7 2011 3 PMC3119915 21576255
  2. [2]Hardy J The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal J Neurochem 8 2009 110 1129 19457065
  3. [5]Ashe KH Zahs KR Probing the biology of Alzheimer’s disease in mice Neuron 10 6 2010 66 631 20547123 PMC2956420
  4. [6]Ebert AD Svendsen CN Human stem cells and drug screening: opportunities and challenges Nat Rev Drug Discov 5 2010 9 367 20339370
  5. [7]Saha K Jaenisch R Technical challenges in using human induced pluripotent stem cells to model disease Cell Stem Cell 4 12 2009 5 584 19951687 PMC2921621
  6. [8]Shi Y Kirwan P Smith J Robinson HP Livesey FJ Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses Nat Neurosci 5 2 2012 PMC3882590 22306606
  7. [9]Wiseman FK Alford KA Tybulewicz VL Fisher EM Down syndrome--recent progress and future prospects Hum Mol Genet 15 4 2009 18 R75 19297404 PMC2657943
  8. [10]Burger PC Vogel FS The development of the pathologic changes of Alzheimer’s disease and senile dementia in patients with Down’s syndrome Am J Pathol 11 1973 73 457 4271339 PMC1904076
  9. [11]Rumble B Amyloid A4 protein and its precursor in Down’s syndrome and Alzheimer’s disease N Engl J Med 1 6 1989 320 1446 2566117
  10. [12]Selkoe DJ Amyloid beta-protein and the genetics of Alzheimer’s disease J Biol Chem 2 8 1996 271 18295 8756120
  11. [13]Rovelet-Lecrux A APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy Nat Genet 1 2006 38 24 16369530
  12. [14]Quon D Formation of beta-amyloid protein deposits in brains of transgenic mice Nature 18 7 1991 352 239 1906990
  13. [15]Woods YL The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase Biochem J 1 5 2001 355 609 11311121 PMC1221774
  14. [17]Vallier L Signaling pathways controlling pluripotency and early cell fate decisions of human induced pluripotent stem cells Stem Cells 11 2009 27 2655 19688839
  15. [19]Chakrabarti L Galdzicki Z Haydar TF Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome Journal Of Neuroscience 24 10 2007 27 11483 17959791 PMC6673208
  16. [20]Chakrabarti L Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome Nat Neurosci 8 2010 13 927 20639873 PMC3249618
  17. [22]Pierfelice T Alberi L Gaiano N Notch in the vertebrate nervous system: an old dog with new tricks Neuron 10 3 2011 69 840 21382546
  18. [23]Klunk WE Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain Life Sci 17 8 2001 69 1471 11554609
  19. [24]Martins-Taylor K Recurrent copy number variations in human induced pluripotent stem cells Nat Biotechnol 6 2011 29 488 21654665
  20. [25]Mummery C Induced pluripotent stem cells--a cautionary note N Engl J Med 2 6 2011 364 2160 21631331
  21. [26]Gore A Somatic coding mutations in human induced pluripotent stem cells Nature 3 3 2011 471 63 21368825 PMC3074107
  22. [27]De Strooper B Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process Physiol Rev 4 2010 90 465 20393191
  23. [28]Gotz J Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform Embo J 3 4 1995 14 1304 7729409 PMC398215
  24. [30]Holtzman DM CSF biomarkers for Alzheimer’s disease: current utility and potential future use Neurobiol Aging 12 2011 32 Suppl 1 S4 22078172 PMC3233690
  25. [33]Qiang L Directed conversion of Alzheimer’s disease patient skin fibroblasts into functional neurons Cell 5 8 2011 146 359 21816272 PMC3151530
  26. [34]Busciglio J Yankner BA Apoptosis and increased generation of reactive oxygen species in Down’s syndrome neurons in vitro Nature 21-28 12 1995 378 776 8524410
  27. [35]Teller JK Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down’s syndrome Nat Med 1 1996 2 93 8564851
  28. [36]Contestabile A Benfenati F Gasparini L Communication breaks-Down: from neurodevelopment defects to cognitive disabilities in Down syndrome Prog Neurobiol 5 2010 91 1 20097253
  29. [37]Holland AJ Hon J Huppert FA Stevens F Incidence and course of dementia in people with Down’s syndrome: findings from a population-based study J Intellect Disabil Res 4 2000 44 Pt 2 138 10898377

Authors
Shi, Y., Kirwan, P., Smith, J., MacLean, G., Orkin, S. H., & Livesey, F. J.
Affiliations
  • University of Cambridge (GB)
  • Boston Children's Hospital (US)
Corresponding author
Livesey, Frederick J.
ORCID
Venue
Science Translational Medicine
Publisher
American Association for the Advancement of Science (AAAS)
Published
2012-03-07
Volume
4
Issue
124
Pages
124ra29-124ra29
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
DOI
10.1126/scitranslmed.3003771
PMC
PMC4129935
OpenAlex
W2152583637
Cited by
310
References
40
Citations by year
2026: 5 · 2025: 6 · 2024: 8 · 2023: 17 · 2022: 16 · 2021: 12 · 2020: 21 · 2019: 27 · 2018: 27 · 2017: 21 · 2016: 18 · 2015: 40 · 2014: 36 · 2013: 35 · 2012: 21
FWCI
28.29
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Wellcome Trust (079249, 092096)
  • Cancer Research UK
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
Keywords
Alzheimer's disease, Down syndrome, induced pluripotent stem cells, cortical neurons, amyloid-beta 42, amyloid precursor protein, gamma-secretase inhibition, tau hyperphosphorylation, amyloid fibril formation, human disease models, embryonic stem cells
MeSH terms
Alzheimer Disease, Cell Differentiation, Cell Line, Down Syndrome, Electrophysiology, Humans, Immunohistochemistry, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, tau Proteins, Embryonic Stem Cells, Induced Pluripotent Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review